arrow
S

Sara Manglaviti

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:13
被引数:477

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unleashing precision: A review of targeted approaches in pleural mesothelioma (vol 203C, 104481, 2024)
2024-12-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma
2024-11-012
OAAI
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

ramucirumab联合卡铂和紫杉醇治疗未治疗的转移性胸腺癌的疗效和安全性: RELEVENT II期试验 (NCT03921671)

2024-09-012
OA
Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy
2024-03-220
PRE
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
2023-11-011
OAAI
Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients

可解释的放射组学,机器和深度学习模型,用于预测晚期非小细胞肺癌患者的免疫检查点抑制剂治疗效果

2023-10-010
OA
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study

延长间隔给药免疫检查点抑制剂的安全性: 一项多中心队列研究

2023-04-124
OAAI
Circulating immature neutrophils early detect hyperprogressive disease upon first-line PD-1/PD-L1 inhibitors in non-small cell lung cancer patients selecting best candidates for platinum-based chemotherapy and PD-1/PD-L1 inhibitors combinations
2023-04-040
PRE
Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients
2023-01-2311
OAAI
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers

人 (NCT03447678),一线II期pembrolizumab试验,在阴性和低PD-L1晚期NSCLC中: 临床结果和与循环免疫生物标志物的关联

2022-12-015
OAAI
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer

循环脂肪酸谱作为晚期非小细胞肺癌免疫治疗的生物标志物

2022-11-015
PRE
Baseline circulating immature neutrophils anticipate hyperprogressive disease (HPD) upon 1st-line PD-1/PD-L1 inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients (pts) and are reduced by platinum-based chemotherapy (PCT) and ICI combinations
2022-09-011
OA